Acute emesis: Moderately emetogenic chemotherapy

Jørn Herrstedt; Bernardo Rapoport; David Warr; Fausto Roila; Emilio Bria; Cynthia Rittenberg; Paul J. Hesketh

doi:10.1007/s00520-010-0951-5

Acute emesis: Moderately emetogenic chemotherapy

Jørn Herrstedt^*
, Bernardo Rapoport
, David Warr
, Fausto Roila
, Emilio Bria
, Cynthia Rittenberg
, Paul J. Hesketh

^*Corresponding author for this work

Research output: Contribution to journal › Review › Research › peer-review

Abstract

This paper is a review of the recommendations for the prophylaxis of acute emesis induced by moderately emetogenic chemotherapy as concluded at the third Perugia Consensus Conference, which took place in June 2009. The review will focus on new studies appearing since the Second consensus conference in April 2004. The following issues will be addressed: dose and schedule of antiemetics, different groups of antiemetics such as corticosteroids, serotonin₃ receptor antagonists, dopamine₂ receptor antagonists, and neurokinin₁ receptor antagonists. Furthermore, antiemetic prophylaxis in patients receiving multiple cycles of moderately emetogenic chemotherapy will be reviewed. Consensus statements are given, including optimal dose and schedule of serotonin₃ receptor antagonists, dexamethasone, and neurokinin₁ receptor antagonists. The most significant recommendations (and changes since the 2004 version of the guidelines) are as follows: the best prophylaxis in patients receiving moderately emetogenic chemotherapy (not including a combination of an anthracycline plus cyclophosphamide) is the combination of palonosetron and dexamethasone on the day of chemotherapy, followed by dexamethasone on days 2-3. In patients receiving a combination of an anthracycline plus cyclophosphamide, a combination of a serotonin₃ receptor antagonist plus dexamethasone, plus the neurokinin₁ receptor antagonist aprepitant on the day of chemotherapy, followed by aprepitant days 2-3, is recommended.

Original language	English
Pages (from-to)	S15-S23
Journal	Supportive Care in Cancer
Volume	19
Issue number	SUPPL. 1
DOIs	https://doi.org/10.1007/s00520-010-0951-5
Publication status	Published - 1 Mar 2011

Funding

Acknowledgement The 2009 MASCC/ESMO Antiemetic Guideline Update Consensus Meeting was funded by unrestricted grants from Eisai Inc, GlaxoSmithKline, Helsinn Healthcare SA, Merck & Co. Inc., and Prostrakan Group. These sources had no role in the design, conduct, or results of the conference, nor in the preparation of data or this manuscript. Additionally, funding was received from the European Society of Medical Oncology (ESMO) and the Multinational Association of Supportive Care in Cancer (MASCC). MASCC organized the meeting. Individual members of either or both these organizations participated in the meeting and preparation of the manuscript.

Keywords

Anthracycline
Chemotherapy
Cyclophosphamide
Dexamethasone
Neurokinin antagonists
Serotonin antagonists

Access to Document

10.1007/s00520-010-0951-5

Cite this

@article{cb754b3dcb504d5b9c3486659db63d2e,

title = "Acute emesis: Moderately emetogenic chemotherapy",

abstract = "This paper is a review of the recommendations for the prophylaxis of acute emesis induced by moderately emetogenic chemotherapy as concluded at the third Perugia Consensus Conference, which took place in June 2009. The review will focus on new studies appearing since the Second consensus conference in April 2004. The following issues will be addressed: dose and schedule of antiemetics, different groups of antiemetics such as corticosteroids, serotonin3 receptor antagonists, dopamine2 receptor antagonists, and neurokinin1 receptor antagonists. Furthermore, antiemetic prophylaxis in patients receiving multiple cycles of moderately emetogenic chemotherapy will be reviewed. Consensus statements are given, including optimal dose and schedule of serotonin3 receptor antagonists, dexamethasone, and neurokinin1 receptor antagonists. The most significant recommendations (and changes since the 2004 version of the guidelines) are as follows: the best prophylaxis in patients receiving moderately emetogenic chemotherapy (not including a combination of an anthracycline plus cyclophosphamide) is the combination of palonosetron and dexamethasone on the day of chemotherapy, followed by dexamethasone on days 2-3. In patients receiving a combination of an anthracycline plus cyclophosphamide, a combination of a serotonin3 receptor antagonist plus dexamethasone, plus the neurokinin1 receptor antagonist aprepitant on the day of chemotherapy, followed by aprepitant days 2-3, is recommended.",

keywords = "Anthracycline, Chemotherapy, Cyclophosphamide, Dexamethasone, Neurokinin antagonists, Serotonin antagonists",

author = "J{\o}rn Herrstedt and Bernardo Rapoport and David Warr and Fausto Roila and Emilio Bria and Cynthia Rittenberg and Hesketh, \{Paul J.\}",

year = "2011",

month = mar,

day = "1",

doi = "10.1007/s00520-010-0951-5",

language = "English",

volume = "19",

pages = "S15--S23",

journal = "Supportive Care in Cancer",

issn = "0941-4355",

publisher = "Springer Science and Business Media Deutschland GmbH",

number = "SUPPL. 1",

}

TY - JOUR

T1 - Acute emesis

T2 - Moderately emetogenic chemotherapy

AU - Herrstedt, Jørn

AU - Rapoport, Bernardo

AU - Warr, David

AU - Roila, Fausto

AU - Bria, Emilio

AU - Rittenberg, Cynthia

AU - Hesketh, Paul J.

PY - 2011/3/1

Y1 - 2011/3/1

N2 - This paper is a review of the recommendations for the prophylaxis of acute emesis induced by moderately emetogenic chemotherapy as concluded at the third Perugia Consensus Conference, which took place in June 2009. The review will focus on new studies appearing since the Second consensus conference in April 2004. The following issues will be addressed: dose and schedule of antiemetics, different groups of antiemetics such as corticosteroids, serotonin3 receptor antagonists, dopamine2 receptor antagonists, and neurokinin1 receptor antagonists. Furthermore, antiemetic prophylaxis in patients receiving multiple cycles of moderately emetogenic chemotherapy will be reviewed. Consensus statements are given, including optimal dose and schedule of serotonin3 receptor antagonists, dexamethasone, and neurokinin1 receptor antagonists. The most significant recommendations (and changes since the 2004 version of the guidelines) are as follows: the best prophylaxis in patients receiving moderately emetogenic chemotherapy (not including a combination of an anthracycline plus cyclophosphamide) is the combination of palonosetron and dexamethasone on the day of chemotherapy, followed by dexamethasone on days 2-3. In patients receiving a combination of an anthracycline plus cyclophosphamide, a combination of a serotonin3 receptor antagonist plus dexamethasone, plus the neurokinin1 receptor antagonist aprepitant on the day of chemotherapy, followed by aprepitant days 2-3, is recommended.

AB - This paper is a review of the recommendations for the prophylaxis of acute emesis induced by moderately emetogenic chemotherapy as concluded at the third Perugia Consensus Conference, which took place in June 2009. The review will focus on new studies appearing since the Second consensus conference in April 2004. The following issues will be addressed: dose and schedule of antiemetics, different groups of antiemetics such as corticosteroids, serotonin3 receptor antagonists, dopamine2 receptor antagonists, and neurokinin1 receptor antagonists. Furthermore, antiemetic prophylaxis in patients receiving multiple cycles of moderately emetogenic chemotherapy will be reviewed. Consensus statements are given, including optimal dose and schedule of serotonin3 receptor antagonists, dexamethasone, and neurokinin1 receptor antagonists. The most significant recommendations (and changes since the 2004 version of the guidelines) are as follows: the best prophylaxis in patients receiving moderately emetogenic chemotherapy (not including a combination of an anthracycline plus cyclophosphamide) is the combination of palonosetron and dexamethasone on the day of chemotherapy, followed by dexamethasone on days 2-3. In patients receiving a combination of an anthracycline plus cyclophosphamide, a combination of a serotonin3 receptor antagonist plus dexamethasone, plus the neurokinin1 receptor antagonist aprepitant on the day of chemotherapy, followed by aprepitant days 2-3, is recommended.

KW - Anthracycline

KW - Chemotherapy

KW - Cyclophosphamide

KW - Dexamethasone

KW - Neurokinin antagonists

KW - Serotonin antagonists

UR - https://www.scopus.com/pages/publications/79953319996

U2 - 10.1007/s00520-010-0951-5

DO - 10.1007/s00520-010-0951-5

M3 - Review

C2 - 20680356

AN - SCOPUS:79953319996

SN - 0941-4355

VL - 19

SP - S15-S23

JO - Supportive Care in Cancer

JF - Supportive Care in Cancer

IS - SUPPL. 1

ER -

Acute emesis: Moderately emetogenic chemotherapy

Abstract

Funding

Keywords

Access to Document

Other files and links

Fingerprint

Cite this